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Introduction {#sec008}
============

On March 11^th^, 2020, the World Health Organisation (WHO) classified the novel coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, as a global pandemic, highlighting the enormity of the viral outbreak \[[@pone.0234187.ref001]\].

Typically, most strains of the coronaviruses family are implicated in causing the common cold. Although this paints the picture of a seemingly benign pathogen; the past two decades have witnessed this family of viruses become implicated in two major epidemics: Middle Eastern Respiratory Syndrome (MERS) through MERS--CoV and Severe Acute Respiratory Syndrome (SARS) caused by SARS-CoV \[[@pone.0234187.ref002]\]. Both viruses share similarities with COVID-19 as they are β-coronaviruses with similar genomic structures. Worryingly, SARS and MERS had case fatality rates (CFR) of 10% and 37% respectively and were responsible for over 10,000 deaths globally. Importantly, they have also been implicated in causing maternal morbidity and mortality \[[@pone.0234187.ref003],[@pone.0234187.ref004]\].

At the time of writing, COVID-19 has a global CFR of \~6.4% and has caused more deaths than MERS and SARS combined \[[@pone.0234187.ref001]\]. Understandably, this raises concerns regarding its effects during pregnancy. This is because pregnancy is associated with physiological changes in women which make them more susceptible to respiratory infections and subsequent rapid progression to respiratory failure. Moreover, the available evidence, based on expert opinion and case series data, suggests expedited delivery to facilitate a 28% reduction in daily oxygen requirements to facilitate maternal respiratory stabilisation during respiratory failure \[[@pone.0234187.ref005]--[@pone.0234187.ref009]\]. Also, when placentas of SARS-affected women were examined, worsening histopathological features of hypoxic damage were appreciable with increasing time from symptom onset to delivery of the fetus, (termed time-to-delivery (TTD) henceforth) \[[@pone.0234187.ref003],[@pone.0234187.ref010]\]. These factors then raise the additional question of whether there were any potential differences in these outcomes with respect to TTD, given the implications it could have for management and prognosis.

Unfortunately, there is a dearth of robust literature to provide guidance to clinicians and patients around these.

Considering this, we performed a systematic review of the literature to better inform clinicians about the maternal and neonatal effects of COVID-19 during pregnancy to facilitate informed decision making.

Methods {#sec009}
=======

This systematic review was conducted in accordance with the PRISMA guidelines. The study protocol and review were not registered with PROSPERO due to the need for urgent information.

Search strategy and selection criteria {#sec010}
--------------------------------------

For the following review, a systematic search was undertaken independently by RW, DS, OP, and MS across PubMed, Ovid Medline and EMBASE from the 1st of November 2019 up until March 28^th^, 2020 with the aid of search information specialist, ROA. Included articles were restricted to those written in the English language.

Search terms utilised across all databases for the study were: ("Covid" OR "coronavirus" OR "SARS-CoV-2" OR "SARS2" OR "2019-nCoV") AND ("antenatal" OR "prenatal" OR "vertical transmission" OR "pregnancy"). A detailed analysis of the search strategy may be found in [S1 Appendix](#pone.0234187.s001){ref-type="supplementary-material"}.

The inclusion criteria of studies for the review were articles relating to pregnant women who were positive for COVID-19. All primary designs were considered, including case reports and case series. Given the infancy of the pandemic, urgent need of guidance, and limited higher quality information available on the topic, this was deemed reasonable. Articles from reference lists of studies being screened were also considered suitable for assessment.

Citations were independently screened by RW, OP, and MS for suitability of inclusion and a set of eligible articles was created in accord. Following shortlisting, the full-text articles were read thoroughly by VS, RW, DS, MS, and OP. Inclusion of an article for the review was based on consensus between these authors. Studies that did not relate COVID-19 with antenatal care, vertical transmission, or pregnancy were excluded. Management guidelines/recommendations, opinion pieces, and reviews consisting of case reports/case series were similarly rejected.

Data analysis {#sec011}
-------------

Information was manually extracted from the full-text articles by DS, VS, MS, OP, RW, and SK. If overlapping data was suspected during examination, efforts were made to identify the more comprehensive dataset for inclusion. To ensure complete datasets, authors of the original articles were contacted, however, at the time of submission, no responses were received.

The pregnancy measures of interest were:

-   Symptoms on presentation

-   Maternal investigations for COVID-19

-   Period between initial symptoms presentation and delivery of the baby (TTD)

-   Preterm delivery (PTD)

-   Mode of delivery

-   Fetal distress, as defined by the authors

-   Intensive care unit (ICU) admission

-   Need for respiratory support

-   Maternal mortality rate

The neonatal outcomes of interest were:

-   APGAR scores at 1 and 5 minutes

-   Birth weight

-   Neonatal symptoms at birth which were defined by the authors as the presence of either fever, lethargy, nausea, respiratory symptoms or intolerance to feeding

-   Neonatal intensive care unit (NICU) admission

-   Neonatal investigations for COVID-19

-   Evidence of vertical transmission

Quality assessment {#sec012}
------------------

Quality assessment was independently performed by RW, OP and DS using the Integrated quality Criteria for Review Of Multiple Study designs (ICROMS) tool developed by *Zingg et al*. It is a versatile tool that can evaluate multiple study designs and is widely used in public health \[[@pone.0234187.ref011]\]. Further details may be found in [S2 Appendix](#pone.0234187.s002){ref-type="supplementary-material"}.

Statistical methods {#sec013}
-------------------

Raw data for the numerical variables in the study were explored for distribution using the Shapiro-Wilk test in tandem with visual plot analysis. Approximately normally distributed data was expressed as mean (±SD) and skewed data was expressed as median (IQR). Categorical variables were expressed as a percentage.

Key baseline characteristics and clinical data were presented as descriptive statistics for the study population where data was available. Meta-analysis or weighted proportions for the outcomes of interest was deemed inappropriate given the sample size and level of missing data.

For the variable TTD, only 12 cases were available for analysis. The outcomes were separated into ≤5 days and \>5 days based on the understanding that this was the median time to development of dyspnoea from symptom onset in hospitalised COVID-19 patients \[[@pone.0234187.ref012]\].

Considering the small sample size, all hypothesis testing to compare proportional differences between the groups were performed using Fisher's exact test.

For all statistical tests, the assumptions of the test were met, and testing was two-tailed. Furthermore, statistical significance was set at an alpha level of p\<0.05.

Statistical analysis was completed using SPSS v25.0.

Patient and public involvement {#sec014}
------------------------------

Patients and members of the public were not involved in this research at any stage.

Results {#sec015}
=======

A total of nine studies (n = 92) out of 73 search results were selected for inclusion in this review \[[@pone.0234187.ref013]--[@pone.0234187.ref021]\]. This is illustrated in [Fig 1](#pone.0234187.g001){ref-type="fig"}.

![PRISMA flow diagram.](pone.0234187.g001){#pone.0234187.g001}

The summary of general characteristics for the included studies are presented in [Table 1](#pone.0234187.t001){ref-type="table"}. The summary statistics for the study are presented in [Table 2](#pone.0234187.t002){ref-type="table"}. [Fig 2](#pone.0234187.g002){ref-type="fig"} provides a summary of the results of the quality assessment process using the ICROMS tool. All studies failed at least one mandatory quality criterion and two, Fan et al. and Wen et al., also failed to meet the minimum required score \[[@pone.0234187.ref014],[@pone.0234187.ref021]\].

![Quality assessment results using ICROMS tool.\
Minimum required score for NCBA is 18 and CBA is 17. Studies which do not meet this score fail the assessment.](pone.0234187.g002){#pone.0234187.g002}

10.1371/journal.pone.0234187.t001

###### General characteristic of included studies.

![](pone.0234187.t001){#pone.0234187.t001g}

  Author                                       Study End Date   Study Design                Location                    Designated maternal hospital (Y/N/NA)   No. of women   Average age of women (Years)   Average Gestational Age (Weeks)   No. of Neonates
  -------------------------------------------- ---------------- --------------------------- --------------------------- --------------------------------------- -------------- ------------------------------ --------------------------------- -----------------
  Chen, H. et al. \[[@pone.0234187.ref020]\]   31st Jan 2020    Retrospective Case Review   Hubei Province, China       Y                                       9              28                             37.3                              9
  Fan, C. et al. \[[@pone.0234187.ref014]\]    19th Feb 2020    Case Report                 Hubei Province, China       Y                                       2              31.5                           36.5                              2
  Li, Y. et al. \[[@pone.0234187.ref016]\]     19th Feb 2020    Case Report                 Zhejiang Province, China    Y                                       1              30                             35                                1
  Liu, D. et al \[[@pone.0234187.ref013]\]     18th Feb 2020    Case Report                 Hubei Province, China       Y                                       15             32                             32                                11
  Liu, H. et al. \[[@pone.0234187.ref015]\]    NA               Case Series                 Hubei Province, China       Y                                       41             30                             31.4                              16
  Liu, Y. et al. \[[@pone.0234187.ref019]\]    25th Feb 2020    Case Series                 Guangdong Province, China   Y                                       13             30                             35                                10
  Wang, S. et al. \[[@pone.0234187.ref017]\]   NA               Case Report                 Hubei Province, China       Y                                       1              34                             40                                1
  Zhu, H. et al. \[[@pone.0234187.ref018]\]    5 Feb 2020       Case Series                 Hubei Province, China       Y                                       9              30                             NA                                10
  Wen, R. et al. \[[@pone.0234187.ref021]\]    20th Feb 2020    Case Report                 Qingdao Province, China     NA                                      1              31                             30                                0

Y--Yes; N--No; NA--Not available.

10.1371/journal.pone.0234187.t002

###### Summary statistical analyses and outcome measures.

![](pone.0234187.t002){#pone.0234187.t002g}

  Descriptive statistics                                                         (n)/N, summary statistic
  ------------------------------------------------------------------------------ ---------------------------
  Age, yr (mean;SD)                                                              \(36\) 30.31 ± 3.80
  Gestational age at presentation                                                \(27\) 35.39 ± 3.51
  Stage of pregnancy                                                             \(27\)
      1^st^ trimester                                                            0
      2^nd^ trimester                                                            2 (7.41%)
      3^rd^ trimester                                                            25 (92.59%)
  Symptomatic on presentation                                                    \(92\) 62 \[67.4%\]
  Fever on admission                                                             \(92\) 57 \[61.96%\]
  Cough                                                                          \(92\) 35 (38.04%)
  Dyspnoea                                                                       \(83\) 10 \[12.05%\]
  Malaise/fatigue                                                                \(82\) 25 \[30.49%\]
  Myalgia                                                                        \(28\) 6 \[21.43\]
  Sore throat                                                                    \(50\) 6 \[12.0%\]
  Nasal congestion                                                               \(4\) 2 \[50%\]
  Diarrhoea                                                                      \(38\) 4 \[10.43%\]
  Lymphopenia                                                                    \(69\) 46 \[66.67%\]
  **Maternal Investigations**                                                    
  CRP, mg/L (median; SD)                                                         \(10\) 18.39 (±9.46)
  RT-PCR performed                                                               \(92\) 84 \[91.3%\]
  RT-PCR result positive                                                         \(84\) 66 \[78.6%\]
  Imaging CT performed                                                           \(79\) 79 \[100%\]
  Pneumonia found from CT                                                        \(79\) 78 \[98.73%\]
  **Maternal Outcomes**                                                          
  Gestation at delivery, weeks                                                   \(13\) 37.47 (±1.45)
  Pre-term delivery[\*](#t002fn002){ref-type="table-fn"}                         \(47\) 30 \[63.83%\]
  \<37 weeks                                                                     \(13\) 6 (46.15%)
  \<34 weeks                                                                     \(0\) 0 (0%)
  Days between symptom and delivery                                              \(12\) 4.33 (± 3.08)
  ICU admission                                                                  \(23\) 1 (4.35%)
  Mode of delivery                                                               \(50\)
      Caesarean section                                                          40 \[80.0%\]
      Vaginal                                                                    3 \[6.0%\]
      On-going pregnancy                                                         7 \[14.00%\]
  Symptomatic post-delivery                                                      \(72\) 28 \[38.89%\]
  Fetal distress (4 ongoing pregnancy)                                           \(18\) 11 (61.11%)
  Perinatal mortality                                                            \(51\) \[3.92%\]
  **Neonatal Outcomes**                                                          
  Birthweight (mean, SD)                                                         \(21\) 2743.81 (± 676.34)
  Birthweight \<2500gm                                                           \(21\) 9 (42.86%)
  APGAR recorded[\*](#t002fn002){ref-type="table-fn"}                            \(33\) 32 (96.97%)
  APGAR 1 min[\*](#t002fn002){ref-type="table-fn"}, (median, 25^th^ to 75^th^)   \(32\) 9 (8--10)
  Apgar \<7 at 1 min                                                             0
  APGAR 5 min[\*](#t002fn002){ref-type="table-fn"}, (median, 25^th^ to 75^th^)   \(23\) 10 (9--10)
  Apgar \<7 at 5 min                                                             0
  NICU admission [\*](#t002fn002){ref-type="table-fn"}                           \(13\) 11 (76.92%)
  Neonate symptomatic of D1[\*](#t002fn002){ref-type="table-fn"}                 \(23\) 12 (52.17%)
  Diagnosed with COVID-19[\*](#t002fn002){ref-type="table-fn"}                   \(21\) 1 (4.76%)

NA--Not available.

\*ongoing pregnancy excluded, n---number of cases, N---total numbers of pregnancies in analysis

Overall, 67.4% (62/92) of women were symptomatic on presentation. The most common presenting symptoms were fever (61.9%; 57/92), cough (38.4%; 35/92) and malaise/fatigue (30.49%; 25/82). 12.1% of women were dyspneic at presentation (10/83).

In terms of investigations, 91.3% (84/92) of the women had RT-PCR (reverse transcription polymerase chain reaction) to confirm the diagnosis of COVID-19. These were positive in 78.6% (66/84) of cases. Pneumonia was diagnosed in 98.73% of cases (78/79) based on CT findings. Lesions included unilateral/bilateral ground-glass opacities and/or unilateral/bilateral consolidations. 23.1% (17/78) of these women had a negative RT-PCR. Additionally, 66.7% (46/69) of women had lymphopenia.

With respect to maternal outcomes, there were no recorded cases of maternal mortality and 4.3% (1/23) required admission to the ICU. In this case, the patient required mechanical ventilation and extracorporeal membrane oxygenation. Amongst hospitalised patients, 28.13% (9/32) required nasal prongs for supplemental oxygen therapy.

The mean TTD was 4.3±3.08 days (n = 12). 63.83% (30/47) of the sample had a preterm delivery (PTD) as an outcome. Amongst these, 46.15% (6/13) were below 37 weeks and none were below 34 weeks. 80.0% (40/50) of women were delivered by Caesarean Section (C-Section). 61.11% (11/18) of cases reported fetal distress with 4 mothers being undelivered in this setting.

In relation to neonatal outcomes, we uncovered a perinatal mortality rate of 3.92% (2/37) (one neonatal death and one stillbirth) in our sample. The stillbirth occurred to the mother who was admitted to the ICU with no discussion of aetiology. At 1 and 5 minutes, APGAR scores of all neonates were greater than 7. Also, 42.86% (9/21) of delivered babies weighed less than 2500g at time of birth (low birth weight), 76.92% (11/13) required NICU admission for additional care whilst 52.17% (12/23) were symptomatic on day 1 of life.

In our series, 2.7% (1/37) had neonatal COVID-19. It is unclear if this is evidence of vertical transmission or if it was contracted post-delivery due to delayed RT-PCR testing 36 hours from birth. With respect to that, 48.64% (18/37) of neonates had RT-PCR testing. Additional COVID-19 testing included: amniotic fluid (24.32%, 9/37), nasogastric content (12.33%, 6/37), and umbilical cord blood (24.32%, 9/37) which were all negative for COVID-19.

Finally, [Fig 3](#pone.0234187.g003){ref-type="fig"} illustrates both maternal and neonatal outcomes with respect to TTD (n = 12). There was no significant difference in the outcomes proportionally when comparing between ≤5 or \>5 days (p\>0.05).

![Relationship between maternal and neonatal outcomes, and time to delivery (TTD).\
DNO---did not occur; NRA---No result available.](pone.0234187.g003){#pone.0234187.g003}

Discussion {#sec016}
==========

During pregnancy, women undergo physiological changes that increase their susceptibility to severe respiratory infections and subsequent respiratory failure--a key concern in relation to COVID-19 infections. The mechanisms mediating this are further described in [S3 Appendix](#pone.0234187.s003){ref-type="supplementary-material"}. Within this discussion, we will also draw comparisons with pregnancy outcomes in analogous *coronaviridae*, SARS and MERS, using two recent rapid reviews \[[@pone.0234187.ref022],[@pone.0234187.ref023]\].

Main findings {#sec017}
-------------

Our study sample had a stark difference in their presenting symptoms with a large proportion being asymptomatic and afebrile at presentation. This contrasts with the hospitalised non-pregnant population. A case series (n = 138) in the disease epicentre, Wuhan, illustrated the following symptomatology: fever (98.6%), cough (59.4%), dyspnoea (31.2%), and malaise (69.6%) with \~1% asymptomatic.^12^ One mechanism implicated in this is the disruption of immunological modulation and homeostasis promoted by the placenta by the viral infection, resulting in altered immunological responses and clinical phenotype \[[@pone.0234187.ref024]\].

66.7% of our sample were lymphopenic. Although associated with a worse prognosis clinically and more severe diseases in the non-pregnant population, it did not appear to translate into poorer outcomes in our study \[[@pone.0234187.ref025]\]. The incidence of lymphopenia in SARS and MERS were 67% and 50% respectively \[[@pone.0234187.ref022]\].

Differences in diagnostic reliability of RT-PCR versus CT were identified. In our sample (n = 79), nearly 23.1% were diagnosed based on imaging studies despite negative RT-PCRs. CTs superior sensitivity has already been documented in the general population (98% vs 71%; n = 51; p\<0.001) \[[@pone.0234187.ref026]\]. Although RT-PCR remains the gold standard for diagnosing COVID-19, clinicians should be aware of the potential for false negatives in pregnant women.

With respect to maternal ICU admissions and mortality rates during COVID-19, the available data appears reassuring. In contrast, SARS and MERS respectively had 15--18% and 25--27% mortality rates; 30% and 60% ICU admission rates, and a requirement for mechanical ventilation in 35% and 41% of women \[[@pone.0234187.ref022],[@pone.0234187.ref023]\].

The PTB rates in our study appear higher than the baseline in China of 6.7% \[[@pone.0234187.ref027]\]. Previously it has been reported that 42.7% of PTB in China were iatrogenic in nature but given the lack of indications for delivery, we are unable to discern the level that this is contributory. It begs consideration, that similar PTB rates occur with MERS (13--25.0%), SARS (0--27%) and parturients with severe viral pneumonia as well, thereby implicating viremia in the process \[[@pone.0234187.ref028]\]. Interestingly, our analysis did not demonstrate any significant differences in PTB rate with respect to TTD \[≤5 days vs \>5 days (66.67% vs 33.33%; p = 0.52)\] from symptoms onset.

Similarly, there was a large proportion of low birth weight (LBW) neonates in our study. Previously, the prevalence of LBW neonates in China were reported as 5.4--6.1% with 61.6--65.3% of PTB babies having LBW too \[[@pone.0234187.ref029],[@pone.0234187.ref030]\]. In our sample, 88.9% (8/9) of LBW infants had PTB. In contrast, only one term baby had LBW, which was significantly different (p = 0.02). Although this suggests associations with PTB, it is useful to consider similar trends in women with SARS and severe pneumonia, where there is also an increased likelihood of having a LBW infant \[[@pone.0234187.ref023],[@pone.0234187.ref031]\]. One mechanism implicated in this is related to the pre-placental hypoxia which can occur as a result of maternal respiratory compromise with pneumonia/pneumonitis. This can perpetuate a cascade of anti-angiogenic and pro-inflammatory factors promoting endothelial dysfunction, end-organ damage, and placental insufficiency; thereby contributing to relative fetal hypoxemia and eventually hypoxia \[[@pone.0234187.ref032],[@pone.0234187.ref033]\]. The high rates of fetal distress in these women enables this argument as it would presumably be mediated similarly.

Our study identified disproportionately high caesarean rates. There are several limitations in interpreting this. Firstly, this may reflect local practice as China has a high baseline caesarean rate (41.5%) \[[@pone.0234187.ref034]\]. Similarly, one would assume that the high levels of fetal distress may have been contributory. Alternatively, expedited delivery may have been required to facilitate rapid maternal stabilisation and improve ventilation. Importantly, there was no substantial evidence supporting any contraindications towards vaginal delivery. To date, expert consensus has mirrored this finding \[[@pone.0234187.ref035],[@pone.0234187.ref036]\].

Our review also demonstrated a high proportion of NICU admissions. These findings were predominantly from the case series by *Zhu et al*. (n = 10) where 60% of the neonates were born premature and all required respiratory support \[[@pone.0234187.ref018]\]. In this sample, two neonates developed disseminated intravascular coagulopathy and one suffered multi-organ dysfunction which resulted in the subsequent neonatal mortality. Additionally, it was identified that nearly half of these neonates were symptomatic on the first day of life. Although none of the neonatal investigations at birth were positive for COVID-19, *Dong et al*. found that serial RT-PCRs for COVID-19 in neonates may appear negative with the neonate demonstrating delayed serological evidence of infection 3--7 days post-infection \[[@pone.0234187.ref037]\]. This raises the possibility of a varied clinical phenotype and suggests that early neonatology input and additional serological testing would be beneficial.

This review identified only one case of neonatal COVID-19. However, the evidence of vertical transmission is unclear or if it was contracted post-delivery because the RT-PCR assay was performed when the infant was 36 hours old. Both SARS and MERS have also previously had no cases of vertical transmission recorded \[[@pone.0234187.ref022],[@pone.0234187.ref023]\].

Strengths {#sec018}
---------

The study informs clinicians and patients regarding the risks of COVID-19 during pregnancy using a larger sample size than the case reports available in the literature which lack the ability to draw firm conclusions. Additionally, this study informs and directs attention towards timing of delivery---a key consideration where no comparable literature exists.

Limitations {#sec019}
-----------

The quality of evidence generated is low due to the small sample size, missing data, potential for reporting bias and the quality of included studies. Additionally, generalising the findings is difficult as the whole study population were from China. Also, as this study incorporates data from hospitalised patients alone, it is unclear if similar findings are extrapolatable to the general pregnant population. As the pandemic evolves, an update will be required with improved data sources to address these aspects.

Interpretation {#sec020}
--------------

The interpretation is as follows:

-   Maternity caregivers should be aware that COVID-19-positive pregnant women can present with an atypical distribution or no symptoms.

-   Hospitalised pregnant women often have pneumonia with COVID-19 infection.

-   RT-PCR, although the gold standard, can have false negatives and may not correlate with CT findings of pneumonia. There is however a significant variation in the swab kits being utilised across regions which may limit the generalisability of this data.

-   There is no available evidence that expedited delivery changes any maternal or neonatal outcomes. This begs consideration in future work in directing delivery timing in COVID-19-positive women.

-   There is no evidence to suggest a contraindication to vaginal delivery.

-   The evidence for vertical transmission appears equivocal.

-   The findings associated with LBW and fetal distress suggests a role for monitoring fetal growth in mothers affected by COVID-19.

-   Early neonatology involvement in a multi-disciplinary approach is prudent given the potential for neonatal/vertical transmission of COVID-19.

Conclusions {#sec021}
===========

The current evidence suggests that there are low rates of maternal and neonatal mortality as well as ICU admissions associated with COVID-19. COVID-19-positive pregnant women however may present with fewer symptoms than the general population and may have equivocal investigations for the disease. The incidence of PTB, LBW, C-section, NICU admission appear higher than the general population. There may be a role for growth monitoring in these fetuses and a multidisciplinary approach is recommended in their care.
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